Fundamental and clinical studies of grepafloxacin in male urethritis

• Published in: Japanese Journal of Chemotherapy Vol. 43; no. Supplement1; pp. 364 - 368
• Main Author: Okazaki, Takejiro
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1995; 公益社団法人 日本化学療法学会
• Subjects: grepafloxacin; ニューキノロン耐性; 淋菌; 男子尿道炎; 臨床検討
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.43.Supplement1_364

Grepafloxacin (GPFX) was administered to 40 male patients with urethritis who visited the Department of Urology, Municipal Taito Hospital, from August 1991 to January 1992. The subjects consisted of 24 cases of gonococcal urethritis, 5 cases of non-gonococcal Chlamydia urethritis, and 11 cases of nongonococcal non-Chlamydia urethritis. GPFX was administered at a dose of 200 or 300mg/day for 2-16 days. In addition, MICs were determined for 23 strains of Neisseria gonorrhoeae from the patients with gonococcal urethritis. N. gonorrhoeae disappeared in 22 of 24 cases (91.2%) of gonococcal urethritis. In diminished cases, the MIC of GPFX was 0.20μg/ml or below, while 2 strains showed MIC values of 0.39 and 0.78μg/ml, respectively. Since some N. gonorrhoeae have recently been found to be resistant to many new quinolone drugs, reexamination of the clinical application of GPFX to gonococcal urethritis seems necessary in the near future. In 5 patients with non-gonococcal Chlamydia urethritis, the pathogen disappeared. Furthermore, 10 of 11 cases of non-gonococcal non-Chlamydia urethritis responded effectively, suggesting the possible application of GPFX to non-gonococcal urethritis. In addition, no adverse reaction was observed in any of the 40 patients treated with GPFX. Thus the drug was considered to be very safe.